Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy
Cancer Letters · 2023-06 · 563 · 216190
DOI: 10.1016/j.canlet.2023.216190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2023-06. Verfasst von Mohan Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya S…. Hauptthemen laut MEDLINE: Neoplasms, Cancer Vaccines, Vaccines, DNA. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 118 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, National Natural Science Foundation of China National Outstanding Youth Science Fund Project.
Abstract (Originalsprache)
Neoantigen is a protein produced by mutant gene, which is only expressed in tumor cells. It is an ideal target for therapeutic tumor vaccines. Although synthetic long peptide (SLP)-based neoantigen vaccine, DNA-based neoantigen vaccine, and mRNA-based neoantigen vaccine are all in the development stage, they have some inherent shortcomings. Therefore, researchers turned their attention to a new type of "non-coding RNA (ncRNA)", circular RNA (circRNA), for potential better choice. Because of its unique high stability and protein-coding capacity, circRNA is a promising target in the field of neoantigen vaccine. In this paper, we reviewed the feasibility of circRNA encoding neoantigens, summarized the construction process, explained the mechanism of circRNA vaccine in vitro, and discussed the advantages and disadvantages of circRNA vaccine and possible combination with other immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, 410013,…
- Key Laboratory of Translational Cancer Stem Cell Research, Department of Pathophysiology, Hunan Normal University School of Medicine, Changsha, Hunan, China.
- Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, 410078, China.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, 410078, China.
- Department of Oral and Maxillofacial Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
- National Natural Science Foundation of China National Outstanding Youth Science Fund Project
Zitieren
APA
Li, M., Wang, Y., Wu, P., Zhang, S., Gong, Z., Liao, Q., Guo, C., Wang, F., Li, Y., Zeng, Z., Yan, Q., & Xiong, W. (2023). Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy. Cancer Letters, 563, 216190. https://doi.org/10.1016/j.canlet.2023.216190
Vancouver
Li M, Wang Y, Wu P, Zhang S, Gong Z, Liao Q, et al. Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy. Cancer Letters. 2023;563:216190. doi:10.1016/j.canlet.2023.216190
BibTeX
@article{Li2023,
author = {Li, Mohan and Wang, Yian and Wu, Pan and Zhang, Shanshan and Gong, Zhaojian and Liao, Qianjin and Guo, Can and Wang, Fuyan and Li, Yong and Zeng, Zhaoyang and Yan, Qijia and Xiong, Wei},
title = {Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy},
journal = {Cancer Letters},
year = {2023},
volume = {563},
pages = {216190},
doi = {10.1016/j.canlet.2023.216190}
}
EUVIMED